Patents by Inventor Nicholas David Cosford

Nicholas David Cosford has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Alkyne derivatives as tracers for metabotropic glutamate receptor binding
    Publication number: 20070060618
    Abstract: The present invention is directed to isotopically labeled alkyne derivative compounds, particularly 11C, 13C, 14C, 18F, 15O, 13N, 35S, 2H, and 3H labeled compounds. In particular, the present invention is directed to 11C, 13C, 14C, 18F, 15O, 13N, 35S, 2H, and 3H labeled heterocyclic alkynes and methods of their preparation. The present invention further includes a method of use of the 11C, 18F, 15O, or 13N labeled heterocyclic alkyne compounds as tracers in positron emission tomography (PET) imaging, particularly in the study of metabolic conditions in mammals, specifically conditions modulated by metabotropic glutamate receptors subtype 5 (mGluR5).
    Type: Application
    Filed: October 24, 2003
    Publication date: March 15, 2007
    Applicant: MERCK & CO., INC.
    Inventors: Nicholas David Cosford, Steven Govck, Terence Hamill, Theodore Kamenecka, Thomas Seiders, Jeffrey Roppe, Celine Bonnefous, Donald Burns, Matthew Braun, Dennis Dean, Joseph Simeone
  • Pyridine derivatives
    Patent number: 6656957
    Abstract: A compound of formula I wherein X represents an optionally halo-substituted (C2-4)alkynylene group bonded via vicinal unsaturated carbon atoms.
    Type: Grant
    Filed: November 27, 2000
    Date of Patent: December 2, 2003
    Assignees: Novartis AG, Sibia Neurosciences Inc.
    Inventors: Hans Allgeier, Yves Auberson, Michel Biollaz, Nicholas David Cosford, Fabrizio Gasparini, Roland Heckendorn, Edwin Carl Johnson, Rainer Kuhn, Mark Andrew Varney, Gönül Veliçelebi
  • MGluR5 antagonists for the treatment of pain and anxiety
    Publication number: 20010056084
    Abstract: The invention provides the use of selective mGluR5 antagonists for the treatment of pain and anxiety, and the use of mGluR antagonists for the treatment of pain, whereby analgesic effect is achieved by interaction of said antagonists primarily or predominantly at peripheral mGluR receptors.
    Type: Application
    Filed: March 29, 2001
    Publication date: December 27, 2001
    Inventors: Hans Allgeier, Nicholas David Cosford, Peter Josef Flor, Fabrizio Gasparini, Conrad Gentsch, Stephen D. Hess, Edwin Carl Johnson, Rainer Kuhn, Mark Tricklebank, Laszlo Urban, Mark Andrew Varney, Gonul Velicelebi, Katharine Walker